Tarlatamab for small cell lung cancer and neuroendocrine cancer
Treatments studied
Part of Cancer clinical trials.
This trial tests a new drug called tarlatamab for people with small cell lung cancer or other neuroendocrine cancers that have spread and have the DLL3 protein. It aims to see if the drug can shrink tumors and understand why some people respond better.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a type of cancer called small cell lung cancer that has spread, or another poorly differentiated neuroendocrine cancer.
- You need to have received at least one previous treatment, including chemotherapy with a platinum drug (like carboplatin or cisplatin).
- Your tumor must have a specific protein called DLL3 (this will be checked with a biopsy).
- You must be willing to have several biopsies (tumor samples) and blood tests during the study.
- You need to be at least 18 years old and in generally stable health.
- You cannot have active brain metastases, certain lung conditions, or severe heart disease.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called Tarlatamab for people with advanced neuroendocrine carcinoma (a rare and aggressive cancer) of the digestive system that has stopped responding to prior chemotherapy. The drug targets a protein called DLL3 found on some tumors, and researchers hope it can shrink or slow tumor growth.
This trial tests a drug called tarlatamab for people with advanced cancers that have a specific protein called DLL3. It aims to see if this treatment can help when other treatments have stopped working.
This trial tests a new immunotherapy drug called tarlatamab, which targets the DLL3 protein on cancer cells, versus standard chemotherapy for people with advanced neuroendocrine carcinoma (NEC). You may qualify if your NEC has gotten worse after just one prior platinum chemotherapy and your tumor has DLL3.
This trial tests a new drug called tarlatamab for people with advanced small cell or neuroendocrine cancers that started outside the lung (like in the stomach, bladder, or head and neck) and have grown after initial chemotherapy. It aims to see if this treatment can shrink or control the cancer.
This study tests a drug called tarlatamab for people with a rare cancer called extrapulmonary neuroendocrine carcinoma that has grown or returned after standard chemotherapy. The goal is to see if tarlatamab can help shrink tumors and improve outcomes.
This trial tests a new drug called tarlatamab, given either as an injection under the skin or through an IV, for people with extensive-stage small cell lung cancer that has grown or come back after one round of chemotherapy. The goal is to see which way of giving the drug works better and is safer.
Hear when a new Metastatic/Locally Advanced Small-Cell Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.